Patents Assigned to Oregon Health Sciences University
  • Methods for enhancing the efficiency of gene editing
    Patent number: 11421218
    Abstract: The present invention provides methods of increasing the efficiency of genome editing.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: August 23, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., Oregon Health & Science University
    Inventors: Alan D'Andrea, Markus Grompe
  • THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20220257516
    Abstract: Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics.
    Type: Application
    Filed: July 13, 2020
    Publication date: August 18, 2022
    Applicants: Oregon Health & Science University, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Moataz Reda, Worapol Ngamcherdtrakul, Ngoc Ha Hoang
  • IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE
    Publication number: 20220249389
    Abstract: Disclosed herein are immunotherapeutic constructs comprising a delivery particle, at least one adjuvant, and one or more therapeutic agents/compounds that cause antigen release and/or modulate immunosuppressive tumor microenvironment. These immunotherapeutic constructs create adaptive immunity or anti-cancer immune response(s) that can be used, for instance, to prevent and treat broad types of cancer. Further disclosed are uses of the immunotherapeutic constructs, including to prevent and treat cancer in humans and animals.
    Type: Application
    Filed: July 12, 2020
    Publication date: August 11, 2022
    Applicants: Oregon Health & Science University, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Worapol Ngamcherdtrakul, Amanda Lund, Moataz Reda
  • ENGINEERED BONE MARROW MODEL
    Publication number: 20220238042
    Abstract: The present invention provides engineered models that recapitulate bone marrow, including the endosteal and vascular niches, and bone marrow diseases. The models can be implemented in many ways including, but not limited to, on a microfluidic device or microfluidic chip, a culture model in vitro, and as an implantable model in vivo. Also provided are methods of using these models, including high-throughput systems and in personalized medicine analysis. Also provided are devices for use in the provided bone marrow models, and kits that include at least one such device.
    Type: Application
    Filed: May 8, 2020
    Publication date: July 28, 2022
    Applicant: Oregon Health & Science University
    Inventors: Negin Mokhtari, Danielle Konetski, Keith Beadle, Anthony Tahayeri, Elie Traer, Luiz Bertassoni, Yu-Jui Chiu, Jesus Bueno Alvarez, Raviraj Thakur
  • CROSS-LINKED POLYMER MODIFIED NANOPARTICLES
    Publication number: 20220211878
    Abstract: Disclosed herein are nanoconstructs comprising a nanoparticle, coated with additional agents such as cationic polymers, stabilizers, targeting molecules, labels, oligonucleotides and small molecules. These constructs may be used to deliver compounds to treat solid tumors and to diagnose cancer and other diseases. Further disclosed are methods of making such compounds and use of such compounds to treat or diagnose human disease.
    Type: Application
    Filed: March 11, 2022
    Publication date: July 7, 2022
    Applicants: Oregon Health & Science University, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Worapol Ngamcherdtrakul, Jingga Morry, David Castro, Joe William Gray
  • In vivo optical flow imaging
    Patent number: 11375913
    Abstract: Described herein is an optical coherence tomograph (OCT) angiography technique based on the comparison of OCT signal amplitude to provide flow information. The full OCT spectrum can be split into several narrower spectral bands, resulting in the OCT resolution cell in each band being isotropic and less susceptible to axial motion nose. Inter-B-scan flow values can be determined using the individual spectral bands separately and then averaged. Recombining the flow images from the spectral bands yields angiograms that use the full information in the entire OCT spectral range. Such images provide significant improvement of signal-to-noise ratio (SNR) for both flow detection and connectivity of microvascular networks compared to other techniques. Further, creation of isotropic resolution cells can be useful for quantifying flow having equal sensitivity to axial and transverse flow.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: July 5, 2022
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Yali Jia, David Huang, Jason Tokayer, Ou Tan
  • Methods and compositions useful in detecting proteins
    Patent number: 11360100
    Abstract: Disclosed herein are compositions, reagents, and methods that can be used to observe multiple targets. The targets can be observed using a variety of methods, for example, by fluorescence, EM, and CLEM. The systems and methods involve the use of self-sorting coiled-coil heterodimers that label multiple proteins in a sample. These compositions, interchangeably termed “VIP tags” herein can be used to efficiently label cellular proteins with high specificity.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: June 14, 2022
    Assignee: Oregon Health & Science University
    Inventors: Kimberly Beatty, Hannah Zane, Julia Doh
  • NEW GENE THERAPY CONSTRUCTS
    Publication number: 20220175966
    Abstract: The present invention provides a new vector for gene therapy said vector being therapeutically very efficient, viral particles comprising said vector, compositions comprising said viral particle, uses thereof, methods for the preparation of the vector), and therapies using said vector.
    Type: Application
    Filed: June 1, 2020
    Publication date: June 9, 2022
    Applicants: ALMA MATER STUDIORUM - UNIVERSITÀ DI BOLOGNA, OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Elisabetta CIANI, Hiroyuki NAKAI, Stefania TRAZZI, Claudia FUCHS
  • Estimating hydration using capillary refill time
    Patent number: 11344254
    Abstract: An example system for estimating a hydration level of an individual can include: a mechanism configured to apply mechanical pressure to a digit of the individual; an light detector configured to sense the light from the digit; and a controller programmed to perform functions including: send a first signal to the mechanism to apply the mechanical pressure to the digit; send a second signal to the mechanism to release the mechanical pressure on the digit; determine a capillary refill time based upon a third signal from the light detector indicating an amount of time for capillaries of the individual to refill with blood; and estimate the hydration level of the individual based upon the capillary refill time and one or more additional parameters.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: May 31, 2022
    Assignees: Welch Allyn, Inc., Oregon Health & Science University
    Inventors: Richard Howard Weitzel, Steven D. Baker, Richard Allen Sunderland, Matthew Lee Hansen, David Clark Sheridan
  • DETECTING AVASCULAR AND SIGNAL REDUCTION AREAS IN RETINAS USING NEURAL NETWORKS
    Publication number: 20220151490
    Abstract: This disclosure describes systems, devices, and techniques for training neural networks to identify avascular and signal reduction areas of Optical Coherence Tomography Angiography (OCTA) images and for using trained neural networks. By identifying signal reduction areas in OCTA images, the avascular areas can be detected with high accuracy, even when the OCTA images include artifacts and other types of noise. Accordingly, various implementations described herein can accurately identify avascular areas from real-world clinical OCTA images. In various implementations, a method can include identifying images of retinas. The images may include thickness images, reflectance intensity maps, and OCTA images of the retinas. Avascular maps corresponding to the OCTA images can be identified. A neural network can be trained based on the images and the avascular maps.
    Type: Application
    Filed: April 24, 2020
    Publication date: May 19, 2022
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Yali Jia, Yukun Guo
  • Amide compounds, pharmaceutical compositions thereof, and methods of using the same
    Patent number: 11325886
    Abstract: Amide compounds are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds as well as methods of treating neurodegenerative diseases that involve administering the compounds or pharmaceutical compositions to a subject.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: May 10, 2022
    Assignee: Oregon Health & Science University
    Inventors: Thomas S. Scanlan, James Matthew Meinig, Skylar J. Ferrara, Tapasree Banerji, Tania Banerji
  • BISPHOSPHONATE-LINKED COMPOUNDS
    Publication number: 20220133894
    Abstract: The present invention concerns novel compounds useful in the treatment of cancer, particularly including compounds linking a bisphosphonate moiety with KBU2046, and pharmaceutically acceptable salts, co-crystals, polymorphs, solvates, hydrates, and enantiomers thereof, as well as methods for their production and pharmaceutical compositions comprising them.
    Type: Application
    Filed: February 6, 2020
    Publication date: May 5, 2022
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Raymond Bergan, Ryan Gordon, Abhinandan Pattanayak
  • METHODS OF TREATING VENETOCLAX-RESISTANT ACUTE MYELOID LEUKEMIA
    Publication number: 20220133715
    Abstract: The present invention concerns novel methods of treatment for venetoclax-resistant acute myeloid leukemia, particularly in subjects with a low expression of TP53 protein or expression of TP53 protein associated with a mutation of the TP53 gene, the methods comprising administering to the subject in need thereof a therapeutically effective amount of a NTRK/ALK/ROS1 inhibitor, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 26, 2020
    Publication date: May 5, 2022
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: JEFFREY TYNER, TAMILLA NECHIPORUK, STEPHEN KURTZ, SHANNON MCWEENY
  • Cross-linked polymer modified nanoparticles
    Patent number: 11305024
    Abstract: Disclosed herein are nanoconstructs comprising a nanoparticle, coated with additional agents such as cationic polymers, stabilizers, targeting molecules, labels, oligonucleotides and small molecules. These constructs may be used to deliver compounds to treat solid tumors and to diagnose cancer and other diseases. Further disclosed are methods of making such compounds and use of such compounds to treat or diagnose human disease.
    Type: Grant
    Filed: August 10, 2021
    Date of Patent: April 19, 2022
    Assignees: Oregon Health & Science University, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Worapol Ngamcherdtrakul, Jingga Morry, David Castro, Joe William Gray
  • Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
    Patent number: 11305015
    Abstract: CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV are provided. Immunization with CMV vectors having the described features allows selection of different CD8+ T cell responses—CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: April 19, 2022
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Louis Picker, Scott Hansen, Klaus Frueh, Daniel Malouli, Jay Nelson, Jonah Sacha, Meaghan Hancock
  • IMMUNOGENIC CONSTRUCTS, COMPOSITIONS, AND METHODS FOR INDUCING IMMUNE RESPONSE
    Publication number: 20220111039
    Abstract: Disclosed are immunogenic constructs including: a nanoparticle; a cationic polymer electrostatically bound to an exterior surface of the nanoparticle and a stabilizer bound to the cationic polymer or the exterior surface of the nanoparticle; and an antigen or antigen producing agent. Optionally, the constructs may include adjuvant and/or one or more functional oligonucleotide(s) (e.g., siRNA or pDNA). Also disclosed are methods of using the provided immunogenic constructs for co-delivering an adjuvant, antigen, and optionally siRNA to a cell, inducing immune response in a subject, and treating or preventing an infectious disease in a subject.
    Type: Application
    Filed: December 15, 2021
    Publication date: April 14, 2022
    Applicants: Oregon Health & Science University, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Sherif Reda, Moataz Reda, Worapol Ngamcherdtrakul, Ruijie Wang
  • Automated detection of shadow artifacts in optical coherence tomography angiography
    Patent number: 11302043
    Abstract: Disclosed herein are methods and systems for automated detection of shadow artifacts in optical coherence tomography (OCT) and/or OCT angiography (OCTA). The shadow detection includes applying a machine-learning algorithm to the OCT dataset and the OCTA dataset to detect one or more shadow artifacts in the sample. The machine-learning algorithm is trained with first training data from first training samples that include manufactured shadows and no perfusion defects and second training data from second training samples that include perfusion defects and no manufactured shadows. The shadow artifacts in the OCTA dataset and/or OCT dataset may be suppressed to generate a shadow-suppressed OCTA dataset and/or a shadow-suppressed OCT dataset, respectively. Other embodiments may be described and claimed.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: April 12, 2022
    Assignee: Oregon Health & Science University
    Inventors: Acner Camino, David Huang, Yali Jia
  • IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE
    Publication number: 20220096628
    Abstract: Disclosed herein are immunotherapeutic constructs comprising a delivery particle, at least one adjuvant, and one or more therapeutic agents/compounds that cause antigen release and/or modulate immunosuppressive tumor microenvironment. These immunotherapeutic constructs create adaptive immunity or anti-cancer immune response(s) that can be used, for instance, to prevent and treat broad types of cancer. Further disclosed are uses of the immunotherapeutic constructs, including to prevent and treat cancer in humans and animals.
    Type: Application
    Filed: December 13, 2021
    Publication date: March 31, 2022
    Applicants: Oregon Health & Science University, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Amanda Lund, Worapol Ngamcherdtrakul, Moataz Reda
  • Device and method for blood volume measurement
    Patent number: 11284823
    Abstract: Disclosed are a method, device and system for determining total circulating blood volume (BV) using a minimally invasive technique.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: March 29, 2022
    Assignee: Oregon Health & Science University
    Inventors: Theodore Hobbs, Ravikant Samatham, Steven L. Jacques
  • THERAPEUTIC FACTOR XII ANTIBODY
    Publication number: 20220089776
    Abstract: Monoclonal antibodies that bind, such as specifically bind, blood protein factor XII (FXII) are described. The monoclonal antibodies (including antigen-binding fragments thereof) are capable of forming immune complexes with human FXII and inhibiting FXII activity, resulting in safe anti-inflammatory and anti-thrombotic effects.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 24, 2022
    Applicants: Oregon Health & Science University, Aronora, Inc.
    Inventors: Michael Wallisch, Andras Gruber, Erik I. Tucker, Christina U. Lorentz